We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Thyroid Hormone Levels Linked to Liver Fibrosis in T2D

By LabMedica International staff writers
Posted on 04 Jul 2022

Nonalcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome and one of its key characteristics is hepatic steatosis which can be caused by excessive accumulation of fat in the liver. More...

The liver plays a crucial role in the metabolism of cholesterol and triglycerides (TG). Meanwhile, thyroid hormones interact on hepatic lipid homeostasis through multiple pathways, including stimulation of free fatty acid delivery to the liver for re-esterification to TG, and increasing fatty acid β-oxidation, thereby affecting hepatic fat accumulation.

Endocrinologists at the Anhui Medical University (Anhui, China) carried out a retrospective analysis that included 586 participants, of whom 55.1% were women. They divided participants into groups 346 with and 240 without NAFLD. A NAFLD fibrosis score of > 0.676 served as the definition for progressive liver fibrosis, which the scientists used to categorize participants into two groups: those with (n = 93) and without (n = 493) progressive liver fibrosis.

After separation of serum, fasting blood glucose (FBG), blood fat, liver function, kidney function and albumin (ALB) were measured using an automatic biochemical analyzer (Hitachi, 7600–020, Tokyo, Japan). Fasting C-peptide (FCP) was detected using enzyme-linked immunosorbent assay Autolumo A2000 Plus (Autobio Diagnostics Co., Ltd, Zheng Zhou City, China). High-performance liquid chromatography was performed for the determination of glycosylated hemoglobin (HbA1c) and flow cytometry and the Sysmex XN9000 (Kobe, Japan) and for the determination of platelets (PLT). Chemiluminescence microparticle immunoassay (Abbott ARCHITECT i4000, Abbott Park, IL, USA) was used to measure FT3, FT4, TT3, TT4 and TSH.

The scientists reported that levels of free triiodothyronine, total triiodomethylamine and free T3/free thyroxine ratio were significantly increased whereas the free T4 level was decreased in the group with NAFLD compared with the group without NAFLD. Additionally, compared with participants without progressive liver fibrosis, those with progressive liver fibrosis demonstrated lower levels of free T3, free T4, total T3 and total T4. In logistic regression analysis, a positive relationship between free T3/free T4 ratio and NAFLD was observed, whereas a negative association was reported between free T4 level and NAFLD, and between the risk for progressive hepatic fibrosis and levels of free T4, total T3 and total T4.

The authors concluded that there is a close correlation between the abnormal thyroid hormone levels and liver fibrosis in type 2 diabetes patients. The prevalence of NAFLD increased following the increase of free T3; free T3/free T4 ratio and decrease of free T4. These results suggested that the change of thyroid hormone level in type 2 diabetes patients should be tested routinely for judging the patient’s condition and predicting the prognosis. The study was published on May 31, 2022 in the journal BMC Endocrine Disorders.

Related Links:
Anhui Medical University 
Hitachi 
Autobio Diagnostics Co., Ltd
Sysmex 
Abbott 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.